Scleral lenses reduce need for surgical intervention in severe keratoconus

scleral-lenses-reduce-need-for-surgical-intervention-in-severe-keratoconus.jpg

FEB 06, 2018

Cornea/External Disease


This retrospective case series suggests that scleral contact lens correction may significantly reduce the rate of transplant surgery in patients with severe keratoconus.

Study design

This retrospective, single-site case series included keratoconus patients with a maximal keratotomy of 70 D or greater. The Microlens rigid scleral lens was fitted by a trained optometrist and ophthalmologist team.

Outcomes

The authors identified 75 eyes for inclusion. Nine had unsuccessful fittings, while 15 eyes did not undergo fitting either because they opted for corneal or hybrid lens wear (3 eyes) or underwent corneal transplantation (12 eyes).

Of the 51 eyes that were successfully fitted for scleral lenses, 7 were lost to follow-up, and 4 could not tolerate the lenses. At a mean of 30 months, all 40 remaining eyes showed better vision with the lenses than with spectacles: The mean BCVA with the scleral lenses was 0.66 decimal fraction, whereas the BCVA with spectacles was 0.13.

Limitations

The retrospective nature of the study introduces challenges in interpreting the results. Without comparing directly to corneal transplantation, conclusions regarding superiority cannot be made. The authors did not highlight the complications associated with scleral contact lens wear.

Clinical significance

The authors demonstrate the successful use of scleral contact lenses in an advanced keratoconus population. They make a valid argument that a scleral contact lens trial may help to validate these findings. Even in seemingly advanced disease, a scleral contact lens can still achieve success and avoid potential complications associated with surgical interventions such as graft-related risks.

View Abstract American Journal of Ophthalmology, January 2018

https://www.aao.org/editors-choice/scleral-lenses-reduce-need-surgical-intervention-i

Comments

Post a Comment

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial.  The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
Read more

Cataract Surgery Leads to Longer Life in Women

Image
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
Read more

Vision Improvements Reported in ProQR’s Clinical Trial for LCA10 Treatment

Image
ProQR, a biotech company in the Netherlands, ha s reported vision improvements for patients in a  Phase 1/2 clinical trial for QR-110 , a therapy for people with  Leber congenital amaurosis  10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world. The company reported that 60 percent of su bjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course . The treatment was also safe for patients. As a result of the encouraging interim results, ProQR has concluded the Phase 1/2 trial and plans to move the treatment into a Phase 2/3 clinical trial. Ten people were treated in the Phase 1/2 study. Results from the interim analy sis were presented on September 5, 2018, at the Retinal Degeneration 2018 meeting in Killarney,   Ireland , by principal investigator   Artur Cideciyan , PhD , research professor of ophthalmology at the   Scheie Eye Ins...
Read more